Kidney Transplantation in Elderly Recipients: A Single-Center Experience.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Historique:
received: 17 01 2018
revised: 02 04 2018
accepted: 13 04 2018
pubmed: 22 1 2019
medline: 29 3 2019
entrez: 22 1 2019
Statut: ppublish

Résumé

In this retrospective single-center study we evaluated the outcome after kidney transplant in recipients older than 65 years in terms of patient and graft survival and causes of death. From 1993 to 2016, 109 consecutive first single kidney transplants in recipients older than 65 years were included. Furthermore, 2 age groups have also been identified (group A, 65-70 years old vs group B, 71-76 years old). Donor and recipient characteristics were analyzed. Other parameters were cold and warm ischemia times, delayed graft function, biopsy-proven acute rejection, and causes of death. Induction immunosuppressive therapy was performed with basiliximab or thymoglobulin. Baseline triple immunosuppression included calcineurin inhibitor, antimetabolite, and steroids. The results of preimplantation biopsies, which were performed in all expanded criteria donors were analyzed and graded according to Karpinski 2009 classification. Overall mortality was 39.4%: 23.2% women and 76.8% men. Causes of death were infections in 42%, tumors in 23%, cardiovascular disease in 14%, cerebrovascular disease in 7%, and unknown in 14%. The most common cause of death in men was infections (52%), and the most common cause in women was tumors (55%). At 1, 3, 5, and 10 years, overall patient survival was 89%, 84%, 72%, and 45%, and overall graft survival was 100%, 97%, 89%, and 84%, respectively. Patient and graft survival were statistically different between group A vs group B (P = .006 and P = .02, respectively). At univariate analysis significant risk factors for increased mortality were age, delayed graft function, and cold ischemia time. At multivariate analysis, delayed graft function maintained statistical significance. Kidney transplantation in patients older than 65 years is safe, feasible, and has good graft survival. Mortality is statistically significant in patients older than 71 years, despite a persistent low graft loss.

Identifiants

pubmed: 30661894
pii: S0041-1345(18)30863-7
doi: 10.1016/j.transproceed.2018.04.081
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

132-135

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

G L Adani (GL)

Department of Medicine, Kidney & Liver Transplantation Academic University Hospital, P. le S.M della Misericordia, Udine, Italy. Electronic address: adanigl@hotmail.com.

U Baccarani (U)

Department of Medicine, Kidney & Liver Transplantation Academic University Hospital, P. le S.M della Misericordia, Udine, Italy.

S Crestale (S)

Department of Medicine, Kidney & Liver Transplantation Academic University Hospital, P. le S.M della Misericordia, Udine, Italy.

R Pravisani (R)

Department of Medicine, Kidney & Liver Transplantation Academic University Hospital, P. le S.M della Misericordia, Udine, Italy.

M Isola (M)

Department of Medicine, Kidney & Liver Transplantation Academic University Hospital, P. le S.M della Misericordia, Udine, Italy.

P Tulissi (P)

Department of Medicine, Kidney & Liver Transplantation Academic University Hospital, P. le S.M della Misericordia, Udine, Italy.

C Vallone (C)

Department of Medicine, Kidney & Liver Transplantation Academic University Hospital, P. le S.M della Misericordia, Udine, Italy.

R Nappi (R)

Department of Medicine, Kidney & Liver Transplantation Academic University Hospital, P. le S.M della Misericordia, Udine, Italy.

A Risaliti (A)

Department of Medicine, Kidney & Liver Transplantation Academic University Hospital, P. le S.M della Misericordia, Udine, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH